Clinical Trial Update: Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating tissue plasminogen activator (alteplase) for the clearance of chronic subdural hematomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Subdural Hematoma

Drugs mentioned

• Activase (alteplase) (alteplase)

Snippet

Sponsor: Hamilton Health Sciences Corporation | Conditions: Hematoma, Subdural, Fibrinolytic; Hemorrhage | Phase 4 | Status: COMPLETED